New York, New York 10016


The investigators plan to compare the impact of two approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life among a diverse population of patients at the Manhattan campus of the VA New York Harbor Healthcare System, which serves a critical safety-net role for urban veterans. During hospitalization, all smokers will receive usual care. Patients will be randomized to one of two arms: financial incentives plus usual care vs. usual care alone, which includes referral to the state Quitline. All patients enrolled in the study will be offered nicotine replacement therapy. The investigators will conduct follow-up assessments at 2 weeks, 2 months, 6 months and 12 months after discharge. The primary study outcome is smoking abstinence at 6-month follow-up, verified by salivary/urinary cotinine.


Inclusion Criteria: 1. age ≥ 18 years, 2. smoked tobacco during the prior 30 days, 3. have an active U.S. phone number and address, 4. can provide consent in English and 5. are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit Exclusion Criteria: 1. use only smokeless tobacco, 2. are pregnant or breastfeeding, 3. are discharged to an institution (e.g., nursing home, long-term care facility), 4. are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study



Primary Contact:

Principal Investigator
Joseph Ladapo, MD, PhD
University of California, Los Angeles

Joseph Ladapo, MD, PhD
Phone: 646-285-7397

Backup Contact:

Scott Sherman, MD, MPH
Phone: 646-285-7397

Location Contact:

New York, New York 10016
United States

Katherine French
Phone: 212-686-7500

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.